Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 6
2004 6
2005 9
2006 10
2007 10
2008 5
2009 3
2010 9
2011 6
2012 6
2013 7
2014 12
2015 9
2016 3
2017 4
2018 7
2019 6
2020 10
2021 6
2022 6
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: fujisawa t. Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23. Cancer Sci. 2022. PMID: 35754298 Free PMC article. Clinical Trial.
[Motilin].
Fujisawa T, Ogihara T. Fujisawa T, et al. Nihon Rinsho. 2005 Aug;63 Suppl 8:517-20. Nihon Rinsho. 2005. PMID: 16149566 Review. Japanese. No abstract available.
[Motilin].
Fujisawa T, Rakugi H. Fujisawa T, et al. Nihon Rinsho. 2010 Jul;68 Suppl 7:556-9. Nihon Rinsho. 2010. PMID: 20960828 Japanese. No abstract available.
Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Masuyama M, Masuda N, Kawaguchi H, Yamamoto Y, Saji S, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S. Masuyama M, et al. Among authors: fujisawa t. Cancer Med. 2023 Sep;12(17):17718-17730. doi: 10.1002/cam4.6390. Epub 2023 Aug 1. Cancer Med. 2023. PMID: 37525895 Free PMC article.
Patients Offer Radiofrequency Ablation Therapy for Early Breast Cancer as Local Therapy (PO-RAFAELO) Study under the Patient-proposed Health Services.
Takayama S, Kinoshita T, Shiino S, Jimbo K, Watanabe KI, Fujisawa T, Yamamoto N, Onishi T, Shien T, Ito M, Takahashi M, Futamura M, Aruga T, Kaneko K, Suto A. Takayama S, et al. Among authors: fujisawa t. JMA J. 2023 Oct 16;6(4):505-512. doi: 10.31662/jmaj.2023-0047. Epub 2023 Oct 2. JMA J. 2023. PMID: 37941717 Free PMC article. Clinical Trial.
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
Iwata H, Yamamoto Y, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Ohtani S, Kashiwaba M, Taira N, Toyama T, Fujisawa T, Masuda N, Shibahara Y, Sasano H, Yamaguchi T. Iwata H, et al. Among authors: fujisawa t. Breast Cancer Res Treat. 2023 Jun;199(2):231-241. doi: 10.1007/s10549-023-06874-7. Epub 2023 Mar 22. Breast Cancer Res Treat. 2023. PMID: 36947277 Free PMC article. Clinical Trial.
132 results